Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential.
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Their team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relieve a variety of chronic disorders and help patients return to normal lives.
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
ESSA Pharma Inc. is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, established in 2009. The company specializes in developing novel therapies for the treatment of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (CRPC). ESSA is advancing its lead product candidate, EPI-7386, which is an oral small molecule designed to selectively block the amino-terminal domain of the androgen receptor (AR). This mechanism targets a critical component necessary for the growth and survival of prostate cancer cells, aiming to address the resistance mechanisms associated with current therapies. By focusing on this specific target, ESSA seeks to enhance the treatment options and improve survival outcomes for patients suffering from CRPC.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
Nuvelution Pharma, Inc. is based in Pembroke, Massachusetts, and provides capital solutions to pharmaceutical and biotechnology companies. The company focuses on facilitating product development through a combination of financial resources and human expertise. By leveraging its extensive knowledge and industry relationships, Nuvelution engages in risk-sharing collaborations that aim to streamline the process of bringing essential medicines to market. This approach is designed to make their model a valuable asset for pharma and biotech firms seeking to advance their product offerings and improve patient access to critical therapies.
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Their team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relieve a variety of chronic disorders and help patients return to normal lives.
Restoration Robotics is a privately held medical device company focused on advancing hair transplantation technology. The company has developed the ARTAS™ System, an innovative image-guided platform that facilitates follicular unit extraction. This system is notable for being the only computer-assisted, physician-controlled robotic solution for harvesting hair follicles, which enhances the precision and efficiency of the hair restoration process. By combining cutting-edge robotics with medical expertise, Restoration Robotics aims to improve outcomes for patients seeking hair restoration solutions.
Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. The company specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology for producing purified, stabilized, and functional GPCRs, known as Stabilised Receptors (StaRs), which addresses a key challenge in drug development. Its research focuses on treatments for conditions such as Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraines. Heptares maintains strategic collaborations with several organizations, including Pfizer and Kymab, to enhance its drug discovery efforts. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.
NanoString Technologies, Inc. is a provider of life science tools for translational research and molecular diagnostics on a global scale. The company specializes in the nCounter Analysis System, an automated platform for digital detection and quantification of nucleic acids. Key products include the nCounter MAX and FLEX systems, which feature an automated liquid handling component and a digital analyzer for data collection. Additionally, NanoString offers the nCounter SPRINT Profiler, nSolver Analysis Software, and custom CodeSets for tailored research needs. The company has developed various gene expression panels for cancer, autoimmune diseases, and other conditions. Furthermore, NanoString is advancing spatial genomics through its GeoMx Digital Spatial Profiler and Hyb & Seq molecular profiling systems. Collaborations with prominent organizations, including Celgene and Merck, enhance its research capabilities, particularly in developing novel protein assays for breast cancer. Founded in 2003 and headquartered in Seattle, Washington, NanoString continues to innovate in the field of molecular diagnostics and research tools.
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
Private Equity Round in 2013
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Avillion LLP, a drug development company, focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers opportunities to partner late phase therapeutic projects for approval, and to accelerate their availability to the market. The company also provides global clinical trial, global regulatory, and CRO management services. It serves pharmaceutical and biotechnology companies. The company was incorporated in 2012 and is based in London, United Kingdom.
NanoString Technologies, Inc. is a provider of life science tools for translational research and molecular diagnostics on a global scale. The company specializes in the nCounter Analysis System, an automated platform for digital detection and quantification of nucleic acids. Key products include the nCounter MAX and FLEX systems, which feature an automated liquid handling component and a digital analyzer for data collection. Additionally, NanoString offers the nCounter SPRINT Profiler, nSolver Analysis Software, and custom CodeSets for tailored research needs. The company has developed various gene expression panels for cancer, autoimmune diseases, and other conditions. Furthermore, NanoString is advancing spatial genomics through its GeoMx Digital Spatial Profiler and Hyb & Seq molecular profiling systems. Collaborations with prominent organizations, including Celgene and Merck, enhance its research capabilities, particularly in developing novel protein assays for breast cancer. Founded in 2003 and headquartered in Seattle, Washington, NanoString continues to innovate in the field of molecular diagnostics and research tools.
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
Private Equity Round in 2012
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Private Equity Round in 2012
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).
Private Equity Round in 2012
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Sientra, Inc. is a medical device company based in Santa Barbara, California, specializing in the plastic surgery and aesthetics market. The company develops and markets a range of products, including silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, aimed at enhancing cosmetic and reconstructive surgery procedures. Sientra focuses on providing innovative and intuitive solutions for plastic surgeons, offering both round and shaped breast implant options to meet diverse patient needs. Through its commitment to quality and innovation, Sientra serves as a key player in the surgical aesthetics industry.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.
NanoString Technologies, Inc. is a provider of life science tools for translational research and molecular diagnostics on a global scale. The company specializes in the nCounter Analysis System, an automated platform for digital detection and quantification of nucleic acids. Key products include the nCounter MAX and FLEX systems, which feature an automated liquid handling component and a digital analyzer for data collection. Additionally, NanoString offers the nCounter SPRINT Profiler, nSolver Analysis Software, and custom CodeSets for tailored research needs. The company has developed various gene expression panels for cancer, autoimmune diseases, and other conditions. Furthermore, NanoString is advancing spatial genomics through its GeoMx Digital Spatial Profiler and Hyb & Seq molecular profiling systems. Collaborations with prominent organizations, including Celgene and Merck, enhance its research capabilities, particularly in developing novel protein assays for breast cancer. Founded in 2003 and headquartered in Seattle, Washington, NanoString continues to innovate in the field of molecular diagnostics and research tools.
Restoration Robotics is a privately held medical device company focused on advancing hair transplantation technology. The company has developed the ARTAS™ System, an innovative image-guided platform that facilitates follicular unit extraction. This system is notable for being the only computer-assisted, physician-controlled robotic solution for harvesting hair follicles, which enhances the precision and efficiency of the hair restoration process. By combining cutting-edge robotics with medical expertise, Restoration Robotics aims to improve outcomes for patients seeking hair restoration solutions.
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop that lowers elevated intraocular pressure in glaucoma patients, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for treating open-angle glaucoma and ocular hypertension. Additionally, Aerie is advancing its clinical-stage product AVX-012 for dry eye and developing sustained-release implants AR-1105 and AR-13503 for retinal diseases. Established in 2005, Aerie is headquartered in Durham, North Carolina, with research facilities in Research Triangle Park. The company has also formed a collaborative research and development agreement with DSM.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
TyRx engages in the design, development, and commercialization of resorbable polymeric biomaterials. It offers PIVIT CRM, a mesh based pouch, which contains antibacterial agents to help provide protection from microbial colonization of the generator or defibrillator during and immediately after surgical implant. The company also provides AIGISRx Flat, an antibacterial product that provides protection against infections associated with implanted pacemakers and defibrillators. TyRx Pharma, Inc. was formerly known as Advanced Materials Design, LLC. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
FerroKin Biosciences
Series B in 2010
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Lycera Corp. is a biopharmaceutical company focused on developing small molecule immunomodulatory medicines aimed at treating autoimmune diseases and cancer. Founded in 2006 and based in Ann Arbor, Michigan, with additional offices in New York and Pennsylvania, Lycera is in the preclinical stage and specializes in first-in-class therapies. Its lead drug candidate, LYC-55716, utilizes multiple anti-tumor mechanisms to modulate gene expression, enhancing immune cell function while reducing immunosuppressive effects. The company also develops ATPase modulators for conditions such as rheumatoid arthritis, lupus erythematosus, psoriasis, and inflammatory bowel disease. Lycera's innovative approach seeks to provide oral efficacy without the adverse effects associated with traditional antiproliferative and immunosuppressive treatments.
NanoString Technologies, Inc. is a provider of life science tools for translational research and molecular diagnostics on a global scale. The company specializes in the nCounter Analysis System, an automated platform for digital detection and quantification of nucleic acids. Key products include the nCounter MAX and FLEX systems, which feature an automated liquid handling component and a digital analyzer for data collection. Additionally, NanoString offers the nCounter SPRINT Profiler, nSolver Analysis Software, and custom CodeSets for tailored research needs. The company has developed various gene expression panels for cancer, autoimmune diseases, and other conditions. Furthermore, NanoString is advancing spatial genomics through its GeoMx Digital Spatial Profiler and Hyb & Seq molecular profiling systems. Collaborations with prominent organizations, including Celgene and Merck, enhance its research capabilities, particularly in developing novel protein assays for breast cancer. Founded in 2003 and headquartered in Seattle, Washington, NanoString continues to innovate in the field of molecular diagnostics and research tools.
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
Neomend, Inc., a biomedical device company, engages in the development and commercialization of surgical wound healing products. Its platform technology, Pro/PEG, is a bioadhesive polymer hydrogel. NeoMend engages in commercialization of the combination wound sealant and adhesion barrier product that can be delivered during minimally invasive/laparoscopic procedures. Neomend, Inc. was founded in 1999 and is based in Irvine, California.
IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.
Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.
FerroKin Biosciences
Venture Round in 2009
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
NanoString Technologies, Inc. is a provider of life science tools for translational research and molecular diagnostics on a global scale. The company specializes in the nCounter Analysis System, an automated platform for digital detection and quantification of nucleic acids. Key products include the nCounter MAX and FLEX systems, which feature an automated liquid handling component and a digital analyzer for data collection. Additionally, NanoString offers the nCounter SPRINT Profiler, nSolver Analysis Software, and custom CodeSets for tailored research needs. The company has developed various gene expression panels for cancer, autoimmune diseases, and other conditions. Furthermore, NanoString is advancing spatial genomics through its GeoMx Digital Spatial Profiler and Hyb & Seq molecular profiling systems. Collaborations with prominent organizations, including Celgene and Merck, enhance its research capabilities, particularly in developing novel protein assays for breast cancer. Founded in 2003 and headquartered in Seattle, Washington, NanoString continues to innovate in the field of molecular diagnostics and research tools.
Lycera Corp. is a biopharmaceutical company focused on developing small molecule immunomodulatory medicines aimed at treating autoimmune diseases and cancer. Founded in 2006 and based in Ann Arbor, Michigan, with additional offices in New York and Pennsylvania, Lycera is in the preclinical stage and specializes in first-in-class therapies. Its lead drug candidate, LYC-55716, utilizes multiple anti-tumor mechanisms to modulate gene expression, enhancing immune cell function while reducing immunosuppressive effects. The company also develops ATPase modulators for conditions such as rheumatoid arthritis, lupus erythematosus, psoriasis, and inflammatory bowel disease. Lycera's innovative approach seeks to provide oral efficacy without the adverse effects associated with traditional antiproliferative and immunosuppressive treatments.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. The company specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology for producing purified, stabilized, and functional GPCRs, known as Stabilised Receptors (StaRs), which addresses a key challenge in drug development. Its research focuses on treatments for conditions such as Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraines. Heptares maintains strategic collaborations with several organizations, including Pfizer and Kymab, to enhance its drug discovery efforts. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
Link Medicine was launched in 2005 by three men with a shared vision: Peter Lansbury, Link's founder and a leading neuroscience researcher from Harvard University, Ed Rudman, a private investor and philanthropist who less than a decade before had been diagnosed with Parkinson's disease, and Adam Rosenberg, an entrepreneur who years before saw his grandfather struggle with Parkinson's disease and his grandmother battle Alzheimer's disease.
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
Globus Medical, Inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. Founded in 2003, Globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. Globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders.
Sientra, Inc. is a medical device company based in Santa Barbara, California, specializing in the plastic surgery and aesthetics market. The company develops and markets a range of products, including silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, aimed at enhancing cosmetic and reconstructive surgery procedures. Sientra focuses on providing innovative and intuitive solutions for plastic surgeons, offering both round and shaped breast implant options to meet diverse patient needs. Through its commitment to quality and innovation, Sientra serves as a key player in the surgical aesthetics industry.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.
VBI Vaccines Inc. is a biopharmaceutical company focused on developing vaccines for infectious diseases and immuno-oncology, with operations in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine suitable for various age groups, and is advancing VBI-2601, an immunotherapeutic candidate aimed at achieving a functional cure for chronic hepatitis B. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to elicit strong immune responses. Key candidates in its eVLP program include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical trials, and VBI-1501, a cytomegalovirus vaccine that has completed Phase I trials. VBI Vaccines also engages in collaboration and licensing agreements with various pharmaceutical and biotechnology entities, including partnerships for the commercialization of its hepatitis B vaccine and the development of a pan-coronavirus vaccine candidate. Headquartered in Cambridge, Massachusetts, the company also has research facilities in Ottawa, Canada.
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.